Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fenofibrate in Diabetic Nephropathy
NCT03869931Phase 3Unknown
- Sponsor
- Singapore General Hospital
- Start
- Mar 2019
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of fenofibrate in diabetic nephropathy (DN), sponsored by Singapore General Hospital. Primary endpoints: Serum concentration of palmitoylcarnitine at 30 days, Serum concentration of acetylcarnitine at 30 days and 4 more. Status: unknown.
02
Drugs
fenofibrate
03
Conditions
diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT03869931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03869931.